Skip to main content

Table 3 Predictive power of M3.M in EU/EEA, Switzerland and Turkey

From: Estimating the effect of practicing nursing professionals density on cumulative carbapenem-resistance prevalence in gram-negative invasive Isolates: a 30 European country observational modeling study

Country

Code

CRGN (%)

PRE_CRGN [CI 95%]

Austria

AT

1.6

1.1% [0.5–2.5%]

Belgium

BE

1.0

0.9% [0.4–2.0%]

Bulgaria

BG

16.6

21.8% [9.6–49.2%]

Croatia

HR

10.6

11.8% [5.4–25.9%]

Cyprus

CY

14.6

10.3% [4.6–23.4%]

Czech Republic

CZ

2.0

4.0% [1.8–9.0%]

Denmark

DK

0.4

0.5% [0.2–1.1%]

Estonia

EE

1.3

0.9% [0.4–2.1%]

Finland

FI

0.5

0.5% [0.2–1.2%]

France

FR

2.5

2.4% [1.1–5.4%]

Germany

DE

1.3

1.1% [0.5–2.5%]

Greece

GR

47.0

37.5% [16.2–86.9%]

Hungary

HU

12.9

9.2% [4.1–20.6%]

Iceland

IS

4.5

4.9% [2.0–12.0%]

Ireland

IE

0.6

1.2% [0.5–2.8%]

Italy

IT

15.2

13.4% [6–30.1%]

Latvia

LV

8.8

8.4% [3.7–19.3%]

Lithuania

LT

5.3

4.9% [2.2–10.7%]

Luxembourg

LU

0.8

1.0% [0.4–2.2%]

Malta

MT

2.8

3.6% [1.6–7.8%]

Netherlands

NL

0.3

0.4% [0.2–0.9%]

Norway

NO

0.4

0.2% [0.1–0.6%]

Poland

PL

8.1

7.3% [3.3–15.9%]

Portugal

PT

5.5

3.4% [1.6–7.4%]

Romania

RO

28.9

27.2% [12.1–61.4%]

Slovak Republic

SK

9.6

10.9% [5–23.9%]

Slovenia

SI

2.5

3.0% [1.3–6.6%]

Spain

ES

2.8

2.1% [0.9–4.7%]

Sweden

SE

0.5

0.3% [0.1–0.7%]

United Kingdom

UK

0.5

1.4% [0.6–3.1%]

Switzerland

CH

0.9

0.4% [0.2–1.0%]

Turkey

TR

30.5

36.3% [14.7–89.8%]

  1. Estimated national cumulative carbapenem resistance proportion (PRE_CRGN) by model M3.M (adj. R2 = 93%) compared to empirical national proportion (CRGN). denotes empirical proportion not covered by M3.M estimation (95% CI)